Abstract Gliomas can diffuse into the normal brain and this invasion of glioma cells involves modification of receptor-mediated adhesive properties of tumor cells, degradation and remodeling of extracellular matrix by tumor-secreted metalloproteinase (MMPs) such as MMP-2, consequently creating an intercellular space for invasion of glioma cells. BmK CT, one of the key toxins in scorpion Buthus martensii Karsch venom, is a novel blocker of the chloride ion channel and MMP-2. In this report, a recombinant plasmid pEGFP-N1-BmK CT was constructed and characterized by in vitro studies. The results showed that pEGFP-N1 mediated BmK CT expression displayed a high activity in suppressing cell migration via MMP-2. The potential therapeutic effect of pEGFP-N1 mediated BmK CT against rat glioma C6 cells was assessed and its potential mechanism was elucidated. It represented an approach for developing a novel therapeutic agent-recombinant plasmid pEGFP-N1-BmK CT as an efficient and powerful adjuvant.
Introduction
Glioma is a highly invasive, rapidly spreading form of brain cancer that is resistant to surgical and medical treatment. Malignant gliomas are the main brain tumors notoriously resistant to currently available therapies, since they fail to undergo apoptosis upon anticancer treatment (Wang and Ji 2005) . Traditional therapy of brain tumors includes surgery, radiation therapy, chemotherapy, and immunotherapy ). Despite these treatments, the median survival time is less than 15 months (Demuth and Berens 2004 ). It's clear that some adjuvant treatment will lead to newer and more effective methods and strategies for brain tumor control in the future.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases involved in the degradation of the extracellular matrix (ECM). The expression level of MMPs correlates with the invasion of cancer cells because the degradation of the ECM is essential for tumor angiogenesis, invasion and metastasis (Gladson 1999; Shao et al. 2011; Li et al. 2011; Lee et al. 2011) . Of note, MMP-2 is up-regulated in gliomas and related cancers, but its expression level is trivial in normal brain tissue (Deshane et al. 2003) , which demonstrates that MMP-2 can be regarded as a potential key target for glioma suppression.
Chlorotoxin (Cltx), one of the key toxins in scorpion Leiurus quinquestriatus venom, has been shown to bind specifically to glioma cell surface as a specific chloride channel blocker (Shen et al. 2005; Yang et al. 2005; Burton et al. 2008) . Results from matrigel invasion assay demonstrate that Cltx can inhibit the enzymatic activity of MMP-2 which is involved in cell migration and specifically up-regulated in gliomas (Deshane et al. 2003) . A chlorotoxinlike peptide gene, BmK CT, was cloned and sequenced from the venom of B. martensii Karsch by Wu et al. (2000) and Zeng et al. (2000) . Similarly, the significance of BmK CT has been well documented as a novel blocker of chloride channel and MMP-2 .
Compared with other vectors (such as viral or nanoparticle vehicles), many cationic lipids naturally occuring or synthesized have been used for gene transfer in the form of liposomes, which have the advantages of non-immunogenicity, simple production, plasmid protected against nuclease degradation, non-oncogenicity, etc. And cationic lipids as an effective alternative of viral vector, and cationic liposomes can be used for cell transfection in vivo and in vitro. Here, we developed a recombinant plasmid pEGFP-N1-BmK CT which was designed to bind and inhibit the activity of the MMP-2. The aim of this study was to assess the antitumor efficacy of BmK CT gene therapy and develop new therapeutic strategy for glioma cancer.
Materials and methods

Materials
Rat glioma C6 cells were kindly provided by Prof. Wang (Institute of Clinical Medicine, Renmin Hospital, Yunyang Medical College, Shiyan, Hubei, China). Dulbecco's modified Eagle's medium (DMEM) was from GIBCO BRL (Life Technologies, Carlsbad, CA, USA). Calf serum was from Hangzhou Evergreen Corp. Lipofectamine 2000 was from Invitrogen (Life Technologies). All reagents used are of highest molecular grade.
Construction of expression plasmid (Fig. 1) The sequence of BmK CT was cloned from pRSETcBmK CT using forward primer (5 0 -AACTCGAGA TGTGCGGTCCGTGCTTC-3 0 ) and reverse primer (5 0 -CGCGGATCCGTAGTAGTAACGGTTGC-3 0 ).
To obtain the pEGFP-N1-BmK CT expression plasmid, the BmK CT sequence was cloned into the pEGFP-N1 plasmid with restriction enzymes Xho I and BamH I.
Cell culture
Cell cultures were prepared and maintained according to standard cell culture procedures. The rat C6 glioma cells were cultured at 37°C in a humidified atmosphere of 5 % CO 2 in DMEM supplemented with 10 % (v/v) heat-inactivated calf serum.
Transfection of recombinant plasmids
For transient transfection, cells were harvested by pancreatin digestion and seeded on microtiter plates. Transfection of plasmids (pEGFP-N1, pEGFP-N1-BmK CT) was performed with Lipofectamine 2000 according to manufacturer's instructions: for 96-well microtiter plates and 24-well microtiter plates, cells were incubated with 0.2 lg plasmid DNA and 0.5 ll Lipofectamine 2000 or 0.8 lg plasmid DNA and 2 ll Lipofectamine 2000, respectively. The pEGFP-N1 containing green fluorescent protein cDNA was used for the observation of transfection efficiency. After 24 h, the transfection efficiency was monitored with a FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).
Gelatin zymography assay
Gelatinolytic activity of MMP-2 and MMP-9 was analyzed by gelatin zymography assay. C6 cells were cultured in the 96-well microtiter plates and the cells transfected with recombinant plasmids were incubated for 24 h. Culture media were then changed to serumfree cell culture media. Serum-free media conditioned for 24 h were subjected to 10 % (v/v) SDS-PAGE containing 0.1 % gelatin. The gel was incubated twice (for 30 min at room temperature) in 2.5 % Triton X-100. The gel was then incubated in activation buffer (5 mM CaCl 2 , 1 mM ZnCl 2 , and 0.005 % Brij, 50 mM Tris/HCl, pH 8.0) at 37°C overnight, stained with Coomassie Brilliant Blue R-250 and briefly destained in 10 % (v/v) acetic acid and 40 % (v/v) methanol. Gelatinolytic activity of MMPs was detected as transparent bands on the blue background.
Western blot analysis
An equal number of C6 glioma cells transfected with recombinant plasmids (pEGFP-N1, pEGFP-N1-BmK CT) were incubated for 24 h. The culture medium was removed. Then cells were washed gently three times with PBS and cultured for another 24 h with culture medium devoid of FBS. Protein was collected from the culture medium. The protein concentration was determined with BCA Protein Assay Kit (Beyotime, Haimen, Jiangsu, China), separated on a 10 % SDS-PAGE gel and then transferred to nitrocellulose membrane. The membrane was blocked and then probed with antibodies against MMP-2 (1:100) (Boster Biotech, Wuhan, China). Goat anti-rabbit IgG was used as the second antibody (1:1500). b-actin in cell lysis solution was probed as control.
In vitro wound healing assay
The effect of EGFP, EGFP-BmK CT on cell migration was examined using in vitro wound healing assay. C6 cells were cultured in the 24-well microtiter plates. After transfection with recombinant plasmids for 24 h, a 'scratch' was introduced by scraping the C6 cells monolayer with a P200 pipette tip and then washed gently three times with cell culture medium to remove cell debris. The cells were then cultured in serum-free culture medium. Percent migration rate (MR %) was calculated as: MR % = (1-T/C) 9 100 %, where T and C represent, respectively, the scrape distance at the indicated treatment times and at the previous treatment time. Results and discussion
Construction and transfection of expression plasmid pEGFP-N1-BmK CT
The over-expression of BmK CT in the cytoplasm is crucial for glioma inhibition in this report. In this study, pEGFP-N1 served as the vehicle to deliver an intact BmK CT gene and an imaging reporter gene to the C6 glioma cells. According to the construction of pEGFP-N1-BmK CT expression plasmid (Fig. 1) , DNA sequence determination confirmed the correct fusion of linker and the target gene (BmK CT) in the vector pEGFP-N1. By counting green fluorescing cells with plasmid pEGFP-N1 transfection, the transfection efficiency of C6 cell line mediated with liposome was above 70 % at 24 h (Fig. 2) . This high-efficiency transfection led to the high level of EGFP or EGFPBmK CT needed to perform the next assays.
pEGFP-N1 mediated BmK CT inhibits the secretion level of pro-MMP-2 MMP-2 appeared to be a major matrix metalloproteinase in gliomas and was absent from normal brain tissue. As shown in Fig. 3a , transparent bands of pro-MMP-2 (*70 kDa), MMP-2 (*60 kDa), pro-MMP-9 (*90 kDa) and MMP-9 (*85 kDa) were detected in the gelatin zymography assay. The activity of pro-MMP-2 was suppressed in the EGFPBmK CT treatment group compared to that in the EGFP and control groups, which demonstrated that, in the cytoplasm, EGFP-BmK CT could also suppress the secretion levels of MMP-2. At the same time, the activity of MMP-9 was suppressed appreciably in the EGFP-BmK CT treatment group since both MMP-2 and MMP-9 have a similar structure. Relative activity was calculated as T/C, where C and T represent, respectively, the densitometry values of pro-MMP-2 in the control group and pro-MMP-2,9 and MMP-2,9 in the treatment group (Fig. 3b) . Western blot confirmed that the expression of MMP-2 was suppressed in the EGFP-BmK CT treatment group compared with that in the EGFP and control groups (Fig. 3c) .
pEGFP-N1 mediated BmK CT expression suppresses the migration of glioma Gelatinase MMP-2 is known to be related with tumor invasion and progression. So, MMP-2 is critical for C6 glioma cells migration and metastasis. As shown in Fig. 4b , the average migration rates of the pEGFP-N1- BmK CT transfection group were lower than of the control group and the pEGFP-N1 transfection group at 6, 12 and 24 h, respectively. Compared to these of EGFP treatment groups, migration rates of C6 glioma cells were suppressed by approx. 66, 76 and 23 % in the presence of EGFP-BmK CT at 6, 12 and 24 h, respectively. These results showed that pEGFP-N1 mediated BmK CT expression displayed a high activity in suppressing cell migration via MMP-2.
Glioma cancer is a problem of or a challenge to clinical treatment. More effective treatment strategies and methods are needed clinically. The combination of some routine treatment methods with new biological therapy may be promising. It has been documented that BmK CT can prevent the metastasis of glioma cells in vivo and 131 I-labeled or Cy5.5-conjugated BmK CT selectively targets glioma in situ (Fan et al. 2010) . Since BmK CT can specifically bind and inhibit the enzymatic activity of MMP-2, the up-regulation of which is partially responsible for the elevated migration ability of glioma cells; we tried to develop a delivery system that specifically targets BmK CT to glioma cells. The delivered BmK CT will then interact with the MMP-2 and/or pro-MMP-2 in the glioma cells. In our previous study, site-directed mutagenesis of BmK CT, wound healing assay, gelatin zymography assay and computational simulation highlighted the importance of electrostatic contribution to BmK CT-MMP-2 catalytic domain complex and a model of BmK CT-MMP-2 catalytic domain complex was proposed (Fu et al. 2011) . It was the first documentation of the structural mechanism of the inhibition of glioma cell migration by BmK CT. Subsequently, we developed a type of glioma-specific multifunctional fluorescent nanodiamonds (FND)-BmK CT which was designed to bind and inhibit the activity of the MMP-2 endopeptidase, and to induce endocytosis of the lipid rafts, subsequently limiting invasive cell activities (Fu et al. 2012) .
Tumor-targeted delivery, biocompatibility and stability are technological challenges in the development of effective nanoparticle (NP)-based diagnostic and therapeutic agents. Despite great progress in recent years, experimental animal studies may never accurately predict the outcome of human clinical trials. Several important questions still need to be answered with respect to the use of nanoparticle vehicles to treat gliomas, such as whether they are able to cross the blood brain barrier, their concentration in tumors, and their mechanism of action within the tumor. Also, the inorganic particles as well as carbon or silica NPs are non-biodegradable. So, these materials cannot be considered as a safe excipient for parenteral pharmaceutical formulations. Therefore, in this study, the potential therapeutic effect of pEGFP-N1 mediated BmK CT against rat glioma C6 cells was assessed in vitro and its potential mechanism was elucidated. The vectors and the gene transfecting methods are the main restrictions of tumor gene therapy. Clinically, liposome-mediated gene transfer is suitable. The findings presented in this work are essential for the further exploration of this gene therapy of glioma tumor. Fig. 4 
